WHWK — Whitehawk Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $165.66m
- $19.96m
- $7.15m
Annual cashflow statement for Whitehawk Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -110 | -60.5 | -65.8 | -63.7 | -20.6 |
| Depreciation | |||||
| Non-Cash Items | 75.3 | 12.5 | 9.34 | 10 | -78.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 12.2 | -1.82 | -3.4 | -6.05 | 1.93 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -22.4 | -49.6 | -59.7 | -59.5 | -97.4 |
| Capital Expenditures | -0.046 | -0.444 | -3.97 | -1.65 | -0.552 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 25.2 | -132 | 87.2 | 26.9 | 12.4 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 25.2 | -133 | 83.2 | 25.2 | 11.9 |
| Financing Cash Flow Items | -9.62 | -0.659 | -0.16 | -0.016 | -5.7 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 142 | 72.6 | 0.326 | 0.13 | 94.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 145 | -110 | 23.9 | -34.2 | 8.83 |